Amlodipine Besylate in Hypertension and Coronary Artery Disease
Amlodipine besylate is a first-line dihydropyridine calcium channel blocker effective for treating both hypertension and coronary artery disease, providing consistent 24-hour blood pressure control with once-daily dosing and cardiovascular event reduction. 1
Mechanism and Indications
Amlodipine works by relaxing blood vessels, allowing blood to flow more easily and reducing blood pressure. It is specifically indicated for:
- Hypertension (as monotherapy or in combination)
- Angina (both chronic stable angina and vasospastic/Prinzmetal's angina)
- Coronary artery disease with or without hypertension 2
Efficacy in Hypertension
- Produces significant reductions in both systolic and diastolic blood pressure, averaging 12-13/6-7 mmHg 1
- Particularly effective for isolated systolic hypertension in elderly patients 1
- Provides consistent 24-hour blood pressure control with once-daily dosing 3
- Maintains normal circadian blood pressure patterns without affecting heart rate 3
Efficacy in Coronary Artery Disease
- Reduces frequency and severity of angina episodes 2, 4
- Increases exercise duration and decreases exercise-induced ST segment depression in patients with coronary artery disease 4
- Associated with fewer hospitalizations for unstable angina and revascularization 5
- Slows progression of carotid artery atherosclerosis as measured by intimal-medial thickness 5
Dosing Guidelines
- Starting dose: 2.5-5 mg once daily
- Maintenance dose: 5-10 mg once daily
- Elderly or hepatic impairment: Start with 2.5 mg once daily
- Can be taken with or without food 2, 1
Use in Special Populations
Hypertension with Coronary Artery Disease
- Amlodipine can be safely used in patients with stable coronary artery disease 6
- Can be combined with beta-blockers for enhanced efficacy in patients with angina 1
- Target BP is <140/90 mmHg, but <130/80 mmHg may be considered in some individuals with CAD 6
Heart Failure
- Unlike non-dihydropyridine CCBs (verapamil, diltiazem), amlodipine can be safely used in patients with heart failure due to systolic dysfunction 6, 1
- The dihydropyridine CCB amlodipine appeared to be safe in patients with severe systolic heart failure in clinical trials 6
Combination Therapy
Amlodipine works well in combination with:
ACE inhibitors or ARBs - particularly effective combination with synergistic effects 1, 7
- Fixed combination of enalapril and amlodipine is effective in normalizing BP in patients with CAD and hypertension 7
Beta-blockers - for patients with angina or post-MI 6
Thiazide diuretics - for enhanced BP control 6
Advantages Over Other Calcium Channel Blockers
- Unlike non-dihydropyridine CCBs (verapamil and diltiazem), amlodipine can be safely used in patients with heart failure with reduced ejection fraction 6
- Provides 24-hour coverage with once-daily dosing due to long half-life 3
- Does not negatively affect heart rate or cardiac conduction 3
Common Side Effects
- Peripheral edema (dose-related, more common in women)
- Flushing
- Headache
- Dizziness
- Fatigue 2
Important Considerations
- When initiating therapy for hypertension with CAD, the BP should be lowered gradually, especially in patients with elevated diastolic BP and evidence of myocardial ischemia 6
- In older hypertensive individuals with wide pulse pressures, monitor for very low diastolic BP values (<60 mmHg) which could compromise coronary perfusion 6
- Avoid non-dihydropyridine CCBs (verapamil, diltiazem) in patients with heart failure with reduced ejection fraction 6
Treatment Algorithm for Hypertension with CAD
First-line therapy:
- Beta-blocker (if post-MI or with angina) plus
- ACE inhibitor/ARB (especially with diabetes, CKD, or LV dysfunction) plus
- Thiazide or thiazide-like diuretic 6
If BP remains uncontrolled or angina persists:
If beta-blockers are contraindicated:
Target BP:
- <140/90 mmHg for most patients
- <130/80 mmHg may be considered in selected high-risk patients 6
Amlodipine has strong evidence for cardiovascular event reduction and should be considered a first-line agent for hypertension, particularly in patients with concomitant coronary artery disease 8.